MedTrace Logo

Big Data and Models for Personalized Head and Neck Cancer Decision Support (BD2Decide)

NCT02832102 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1450

Last updated 2016-07-14

No results posted yet for this study

Summary

The purpose of this study is to determine new multiscale signatures for the prediction of head and neck cancer (HNC) patients disease outcome, in particular for advanced stage (stage III, IV) human papillomavirus (HPV) negative patients and to validate prognostic models for overall survival.

Conditions

  • Cancer of Head and Neck

Interventions

PROCEDURE

Standard treatment of SCCHN patients

The interventions may include surgery, radiotherapy, chemotherapy or combined therapies, as recommended by best practice and international guidelines.

Sponsors & Collaborators

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

    collaborator OTHER

  • Amsterdam UMC, location VUmc

    collaborator OTHER

  • Heinrich-Heine University, Duesseldorf

    collaborator OTHER

  • Maastricht Radiation Oncology

    collaborator OTHER

  • Istituto Superiore di Sanità

    collaborator OTHER

  • Azienda Ospedaliero-Universitaria di Parma

    lead OTHER

Principal Investigators

  • Tito Poli, MD, PHD · Azienda Ospedaliero-Universitaria di Parma

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • Germany
  • Italy
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02832102 on ClinicalTrials.gov